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Abstract TBX3, the gene mutated in ulnar-mammary
syndrome (UMS), is involved in the production of a
transcription factor of the T-box family, known to inhibit
transcription from the p14ARF (p19ARF in mouse) pro-
moter in fibroblasts and to contribute to cell immortaliza-
tion. One of the main features of the UMS phenotype is the
severe hypoplasia of the breast, associated with haploin-
sufficiency of the TBX3 gene product. In mice homozygous
for the targeted disruption of Tbx3, the mammary glands
(MGs) are nearly absent from early stages of embryogen-
esis, whereas in heterozygous adults, the MGs show
reduced ductal branching. All these data strongly suggest
a specific role of TBX3 in promoting the growth of
mammary epithelial cells (MECs), although direct evidence
of this is lacking. Here, we provide data showing the
growth-promoting function of Tbx3 in several models of
MECs, in association with its ability to repress the ARF
promoter. However, no effect of Tbx3 on cell differentiation
or apoptosis has been observed. The growth promoting
function also entails the down-regulation of p21CIP1/WAF
and an increase in cyclin D1 but is independent of p53
and Mdm2 cell-cycle regulatory proteins, as p53-null
MECs show similar growth responses associated with the
up- or down-regulation of Tbx3. This is the first direct
evidence that the level of Tbx3 expression positively
controls the proliferation of MECs via pathways alternative
to Mdm2-p53.
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Introduction
The mammary gland (MG) undergoes a complex series of
changes from intrauterine life to senescence. The various
stages of MG development include embryonic, prepubertal
and pubertal phases, plus pregnancy, lactation and involu-
tion (Daniel and Smith 1999). Development of the MG is
initiated in early mammalian embryos and undergoes a com-
plex morphogenesis that results in the formation of primary
ducts and the end-bud (Hennighausen and Robinson 1998;
Veltmaat et al. 2003; Rowley et al. 2004). Growth and
morphogenesis continue mainly at puberty under the
influence of hormones and entail massive proliferation of
multipotent cells, duct extension and branching. Finally, the
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organization of a functionally differentiated and mature MG
occurs cyclically with each pregnancy, followed by the
lactation and involution phases. Embryonic and pre-
pubertal growth of the MG is referred to as being hormone
independent, whereas pubertal growth and pregnancy-
dependent maturation require specific sexual hormones
(Visvader and Lindeman 2003; Groner 2002).
During all these steps, signals between the epithelium
and the surrounding mesenchyme and stroma are critical; in
particular, during embryonic growth, several molecules
(such as members of the Wnt and fibroblast growth factor
families) convey signals that induce placode formation and
thickening, followed by duct elongation and primitive
branching (Hennighausen and Robinson 1998; Rowley et
al. 2004). Together with the expansion of the mesodermal
component of the MG, these events collectively result in
the morphogenesis of the gland. Transcription factors and
co-factors (such as members of the LEF, Msx and Hox
families) present in the epithelial cells mediate the response
to extracellular signals by regulating the transcription of
target genes (for reviews, see Rowley et al. 2004; Visvader
and Lindeman 2003; Groner 2002; Coletta et al. 2004).
Little is known about transcription factors controlling the
intrinsic growth potential of mammary epithelial cells
(MECs).
The highly regulated process of growth, morphogenesis
and differentiation of the MG is impaired in patients with
ulnar-mammary syndrome (UMS, OMIM 181450). UMS is
characterized by upper limb skeletal malformations, severe
hypoplasia of the breast and other apocrine glands, and hair
and genital defects. In UMS patients, one allelic copy of the
TBX3 gene is mutated, often resulting in the synthesis of a
truncated non-functional protein and insufficient level of
wild-type (WT) TBX3 protein (a transcription factor of the
T-box family), a situation known as haploinsufficiency
(Bamshad et al. 1997, 1999; Meneghini et al. 2006). The
loss of one functional TBX3 allele in UMS patients results
in a severe congenital reduction or absence of the epithelial
component of the MG. Thus, the precise level of TBX3
gene expression and, consequently, the expression of its
transcriptional targets appear to be critical for the control of
the proliferation of mammary epithelial cells in vivo.
Germ-line and somatic inactivation of Tbx3 in the mouse
has been achieved (Davenport et al. 2003). Homozygous
animals show UMS-related defects in a severe form and the
mammary buds are absent by E13 and all subsequent
stages, as evidenced by lack of expression of the early
markers Wnt10b and Lef1 (Davenport et al. 2003), whereas
heterozygous appear to be normal. This outcome might
have been expected based on the phenotype of “knock-out”
mice for other Tbx genes, e.g. for Tbx4 (Packham and
Brook 2003; Naiche and Papaioannou 2003). Regrettably,
Tbx3−/− embryos do not survive past E15-E16 and thus are
of little use in the examination of mammary growth and
histological organization as a consequence of Tbx3 inacti-
vation. Recently, Jerome-Majewska and collaborators
(2005) have carried out a detailed analysis of the MG of
Tbx3+/− females and report reduced branching of the ductal
tree. It is still unclear whether the reduced branching is a
direct consequence of the loss of one Tbx3 alleles, in other
words whether a cell-autonomous property is directly
regulated by the level of Tbx3 expression in MECs.
T-domain-containing genes (Tbx) are members of a
highly conserved family of transcription factors that share
a common DNA binding (T) domain (Papaioannou and
Silver 1998; Smith 1999), which is essential for sequence-
specific DNA binding and transcription activation or
repression of target genes (Papaioannou and Silver 1998;
Smith 1999; He et al. 1999; Wilson and Conlon 2002;
Paxton et al. 2002; Butz et al. 2004). Some target genes
have been identified (Tada and Smith 2001; Lingbeek et al.
2002), but not in MECs, the main cellular target in the
UMS phenotype; in these cells, Tbx3 transcription
regulation is likely to be the result of cell-type-specific
DNA binding and expression of the target genes. In non-
mammary cells TBX3 has been shown to repress the
transcription of ARF potently (p14ARF in human, p19ARF
in mouse; Lingbeek et al. 2002; Carlson et al. 2001;
Brummelkamp et al. 2002), a positive regulator of the
p53 pathway and also known as cyclin-dependent kinase
inhibitor 2A (CDKN2A). The repression of p14ARF by
TBX3 leads to cell immortalization of neuronal and
embryonic fibroblasts (EF) (Carlson et al. 2001;
Brummelkamp et al. 2002), an indication that the
p14ARF gene might lie genetically downstream of TBX3
in these cells.
As mutations in the TBX3 gene cause the breast
hypoplasia seen in UMS, and as Tbx3 expression is found
predominantly in the epithelial component of the embry-
onic mammary bud and the postnatal MG (Davenport et al.
2003; Jerome-Majewska et al. 2005; Chapman et al. 1996),
we might logically expect that Tbx3 has a positive role in
the regulation of MECs growth, possibly by repressing
p19ARF. In support of this hypothesis, the over-expression
of Tbx3 in mouse EFs and other non-epithelial cells leads to
the onset of indefinite proliferation (Carlson et al. 2001;
Brummelkamp et al. 2002). However, TBX3 gene function
should best be assessed in MECs, because the cell-type
specificity of transcription regulation is likely to be co-
determined by cell-type restricted co-factors (Tada and
Smith 2001). This notion is particularly relevant since Tbx3
and Tbx2, unlike other T-domain proteins, are known to be
transcriptional repressors (Carreira et al. 1998; He et al.
1999; Carlson et al. 2001).
No data are available for MECs, the main cellular targets
of TBX3 mutations in vivo. Furthermore, little is known
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about the Tbx3 expression profile during postnatal MG
growth and functional differentiation or about whether
Tbx3 can repress p19ARF and act through a p53-dependent
or p53-independent pathway of cell-cycle regulation. In the
present study, we have addressed the cellular functions of
TBX3 by using the immortalized non-tumorigenic HC11
MECs that lack WT p53 as our main in vitro model
(Danielson et al. 1984). These cells can partially differen-
tiate in vitro, as they synthesize milk proteins following
lactogenic hormone induction (Ball et al. 1988), a feature
used in previous studies in which growth-promoting and
inhibitory genes have been found to interfere with
differentiation (Merlo et al. 1996). HC11 cells have the
additional property to undergo apoptosis under specific
serum-/growth-factor-deprivation conditions, reminiscent of
the events occurring during the post-weaning involution of
MGs (Merlo et al. 1995). Here, we show that TBX3/Tbx3
regulates the growth of several MEC lines independently of
p53, whereas the differentiation and apoptotic properties of
these cells remain unchanged. TBX3 can repress p19ARF
expression at the promoter level regardless of the p53.
Exogenous expression of TBX3 results in the reduced
expression of the CDK inhibitor p21CIP1/WAF, whereas the
expression of Mdm2 remains unaffected. We propose that
TBX3-dependent growth promotion in MECs occurs via
p19ARF and p21CIP1/WAF, but independently of the Mdm2-
p53 pathway.
Materials and methods
Expression and reporter vectors
The haemagglutinin (HA)-epitope-tagged TBX3 expression
vector (based on pCS2+) was provided by Drs. Hurlin and
Ota (Carlson et al. 2001). This vector, which lacks a
suitable selectable marker, was used solely in transient
transfection experiments in COS7 and HC11 cells. For
transfection and selection of clones, the HA-TBX3 cDNA
was subcloned into the BamHI/SnaBI sites of the pBabe-
puro vector (Morgenstern and Land 1990), carrying the
puromycin-resistence selectable marker. The p14ARF
luciferase-reporter construct was provided by Dr. M.
Lingbeek (Lingbeek et al. 2002) and was used to assay
for TBX3-dependent repression in MECs by transient
transfection. The vector contains the −19/+54 region of
the p14ARF promoter introduced into the pGL3-basic
vector (Promega).
Cell cultures and treatments
HC11 mouse MECs (provided by Dr. N. Hynes, FMI,
Basel) were maintained at 37°C/5% CO2, in growth
medium (GM) composed of RPMI-1640, 8% heat-inacti-
vated fetal calf serum (FCS), 5 μg/ml insulin (Sigma) and
10 ng/ml murine epidermal growth factor (EGF; Sigma),
glutamine and gentamycin (Merlo et al. 1994). For the
differentiation assay, confluent cultures of HC11 cells were
incubated in induction (DIP) medium containing
RPMI1640, 8% FCS, 1 μM dexamethasone, 5 μg/ml ovine
prolactin (Sigma) and 5 μg/ml insulin. Reduced medium
contained RPMI-1640, 1% heat-inactivated FCS, 5 μg/ml
insulin, glutamine and gentamycin. Serum-free medium
(SFM) was prepared by adding 2% bovine serum albumin
(BSA; Sigma) to RPMI. NulliB cells were derived from
p53−/− mice (provided by Dr. D. Medina, Baylor College
of Medicine, Houston, Tex.). These cells were maintained
in RPMI, 2% FCS, 10 μg/ml insulin and 5 ng/ml EGF,
glutamine and penicillin-streptomycin. LA7 and 106A10
rat MECs were cultured in DMEM, 10% FCS, insulin and
hydrocortisone (50 ng/ml each) and penicillin-streptomy-
cin. For the differentiation assay, confluent cultures of LA7
and 106A10 cells were exposed to 2% dimethyl sulphoxide
(DMSO; Dulbecco et al. 1980). MDA435 and MCF7 breast
cancer cells were maintained in DMEM with 10% FBS
penicillin-streptomycin.
For depletion of the endogenous TBX3/Tbx3, we used
four 21-nucleotide antisense oligonucleotides (AS oligos),
three designed from the Tbx3-coding region, and one from
the 3′-untranslated region (sequences provided in Tables 1, 2).





Mouse Tbx3 5′-TTGCAAAGGGTTTTCGAGAC 5′-GTTGGATGTCCCCACGAT 60 191
Human TBX3 5′-GCAGCTTTCAACTGCTTCG 5′-CCTCGCTGGGACATAAATCT 59 88
Mouse p19ARF 5′-CCCACTCCAAGAGAGGGTTT 5′-TCTGCACCGTAGTTGAGCAG 55 199
Mouse mdm2 5′-AGGGCACGAGCTCTCAGAT 5′-GAAGCCAGTTCTCACGAAGG 60 200
Mouse p21CIP1/WAF 5′-GGACAAGAGGCCCAGTACTTC 5′-TCTGCGCTTGGAGTGATAGA 58 187
Mouse β-casein 5′-GTTCAGGCTTTTCCTCAGAC 5′-CCATGGGTCGAATTCAAATG 60 393
Mouse cyclin D1 5′-GAGATTGTGCCATCCATGC 5′-CTCTTCGCACTTCTGCTCCT 55 75
Mouse GAPDH 5′-TGTATGCAGGGATGATGTTC 5′-TGTCAGCAATGCATCCTGCA 61 190
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For chosing the appropriate sequences, we avoided regions
of Tbx3 mRNA likely to be involved in the formation of
intra-molecular base pairing and secondary structures or
regions partially conserved between T-box genes. Dependent
on the employed cell line (murine/human), species-specific
AS oligos were used. Sequences were verified by BLAST
searches. Four control sense oligonucleotides (S oligos) were
designed complementary to the AS oligos. For p19ARF, we
used two 21-nucleotide AS oligos corresponding to se-
quences of the alternative-spliced exon 1β of the INK4a/
ARF locus (see Tables 1, 2).
Oligomers were added three times a day for 3 days
directly to the culture medium onto newly plated adherent
cells (<20% confluency) at a total concentration of
0.25 mg/ml/day (Zucchi et al. 1998, 1999). To verify the
down-regulation by AS oligos, total RNA was extracted
from cells growing for 72 h and the relative abundance was
determined by real-time quantitative polymerase chain
reaction (qPCR, see below).
For the monolayer cell proliferation assay, cells were
seeded in 96-wells clusters at the starting density of 5,000
cells/well. After the cells were attached, the first point (time
0) was taken, the subsequent points being taken 24, 48 and
72 h later. The number of viable cells was determined with
the Cell Proliferation Kit I (MTT, Roche) according to
manufacturer’s instructions. Measurements were performed
on triplicate points in an enzyme-linked immunosorbent
assay reader at a wavelength of 600 nm and standard
deviations were determined.
Programmed cell death was induced in MECs as
described (Merlo et al. 1996). Briefly, cells were plated on
chamber slides in GM. At confluence, cells were treated
with SFM or with SFM plus EGF (10 ng/ml) for 48 h and
then analysed. Two methods were used. For direct
examination and counting, cells were fixed in 2% parafor-
maldehyde for 10 min, rinsed and stained with a solution
containing 6′-diamidino-2-phenylindole (DAPI, 1:2,000),
0.1% Triton X-100, 0.1% Na citrate and 20 μg/ml RNaseA.
Nuclei with morphological features of apoptosis were
identified and counted. Alternatively, a flow-cytometric
apoptotic assay was used to detect Annexin V-positive
cells, corresponding to early apoptotic cells (Koopman et
al. 1994), by using FACScan equipment (Becton-Dickinson),
with Ex=488 nm, Em=530 nm. The assay was followed by
the Annexin V-fluorescein isothiocyanate (FITC) Apoptosis
Detection kit (MBL) according to the manufacturer’s
protocol. In this assay, Annexin V-negative and propidium
iodide (PI)-positive signals corresponded to nuclear debris,
Annexin V-positive and PI-positive signals corresponded to
late apoptotic cells, Annexin V-negative and PI-negative
signals corresponded to live cells and Annexin V-positive
and PI-negative signals corresponded to early apoptotic
cells. The experiments were repeated twice and standard
deviations were calculated.
Transfection and reporter assays
For transient transfection, cells were transfected for 48 h
with pCS2+HA-TBX3 plasmid by using Lipofectamine-
2000 (Invitrogen), according to the manufacturer’s instruc-
tions. Transfected cells were either immunostained with
anti-HA antibody (Y11, Santa Cruz Biotechnology) or used
to prepare total protein lysates for Western blot analysis
with the same antibody.
For the generation of cell lines expressing exogenous
HA-TBX3, HC11 cells were seeded in duplicate in 35-mm
dishes at a density of 2×105 cells per dish; 24 h later, cells
were transfected with 4 μg HA-TBX3-pBabe-puro plasmid
by using Lipofectamine-2000 and, after an additional 48 h,
the cells were trypsinized, replated and cultured in GM
containing puromycin (2.5 μg/ml) for 10–14 days before
individual clones were picked and further propagated. The
resulting clones were tested for the presence of HA-TBX3
protein by Western blot analysis and by immunostaining
with anti HA-antibody.
For the reporter assay, transfections were carried out
with Lipofectamine-2000, with 4 μg of the (−19/+54)
p14ARF-luciferase reporter plasmid, 5 μg of the pCS2+HA-
TBX3 expression plasmid (or an equal amount of empty
plasmid, as control) and 400 ng of a CMV-βgal plasmid to
normalize for transfection efficiency. Prior to transfection,
cells were plated in 6-well cluster dishes at a density 4×105
cells per well, in duplicates. Cells were cultured for 48 h
and then lysed and assayed for promoter activity with the
Luciferase Assay System (Promega). Luminescence values
were normalized for β-gal activity levels and for total
protein concentration in the lysates. Experiments were
repeated three times.
Western blot and immunofluorescence analyses
For Western blot analyses, total proteins were extracted
with RIPPA lysis buffer containing 150 mM NaCl, 50 mM
Table 2 Antisense (AS) oligonucleotides used
Oligonucleotide type Sequence




AS human TBX3 1. 5′ ACTTTAAATGGAGGAAACATT
2. 5′ TTTGTGGAAAGTGACGACTTT
3. 5′ GCAAAAGGGTTGTTGTCTATT
AS p19ARF 1. 5′ACAGTGACCAAGAACCTGCGA
2. 5′TTCACGAAAGCCAGAGCGCAG
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TRIS-HCl (pH 8.0), 1% NP40, 0.1% SDS, 1 mM phenyl-
methane sulphonyl-fluoride and 1:1,000 “protease cocktail
inhibitor” (Sigma) for 15 min on ice, followed by
sonication (2–3 W, 20 s). After centrifugation, the cleared
lysates were resolved on 10% SDS-polyacrylamide gels,
transferred to polyvinylidene fluoride membranes (Hybond,
Amersham) and developed by using standard electrochem-
iluminescent procedures (Amersham). Primary antibodies
were: rabbit anti-HA (Y11, Santa Cruz Biotechnology)
used at a dilution of 1:200; rabbit anti-mouse milk proteins
(from Dr. Hynes, FMI Basel) at 1:300; rabbit anti-p19
(Abcam) at 1:500. For the detection of milk proteins, 5%
BSAwas used as a blocking agent. Secondary antibody was
peroxidase-conjugated goat anti-rabbit (Amersham) at
1:8,000.
For immunostaining, cells were plated on glass chamber
slides (BD, Falcon) in GM, incubated for 24 h, fixed in
methanol/acetic acid (3:1) for 5 min and rinsed with
phosphate-buffered saline (PBS). After permeabilization
with 0.5% Triton X-100, cells were incubated with 10%
goat serum and then with anti-HA antibody (1:200)
overnight at 4°C. As the secondary antibody, FITC-
conjugated anti-rabbit antibody was used (1:100). Nuclei
were counterstained with DAPI (1:2,000).
RNA extraction, cDNA synthesis and real-time qPCR
Cells or MG tissues were harvested in TriPure Isolation
Reagent (Invitrogen) and total RNA was purified according
to the manufacturer’s instructions. RNA was quantified by
using a NanoDrop Spectrophotometer ND1000. Total RNA
(1 μg) was reverse-transcribed at 42°C for 50 min with
random hexamers and SuperScriptII Reverse Transcriptase
(Invitrogen). Relative cDNA abundance was measured by
qPCR with a LightCycler 1.5 (Roche). Reactions were set
up with the Fast Start DNA Master SYBR Green Kit
(Roche) according to the manufacturer’s protocols. All the
sample cDNAs and a calibration sample were amplified
with specific oligonucleotide primers (see Tables 1, 2),
previously validated for efficiency and specificity of
amplification (denaturation profiles). Standard dilution
curves were determined for every target cDNA. Samples
were analysed in triplicate. To normalize for the amount of
total RNA used in each reaction, we carried out amplifica-
tion of mRNA for the house-keeping gene GAPDH (D-
glyceraldehyde-3-phosphate dehydrogenase). Experiments
were repeated twice on independent samples. Data analysis
was performed with LightCycler software 3.5. (Roche).
Cell-cycle analysis
HC11 cells were plated in 6-well cluster dishes at a density
of 7.5×104 cells/dish in GM and treated with AS Tbx3
oligos as above. Cells were then trypsinized, fixed in
ethanol 70% at 4°C and stored at 4°C. For analysis, 1–2×
106 cells were washed, resuspended in PBS containing
10 μg/ml PI (Sigma) and 12.5 μl RNase and kept at 4°C for
at least 12 h. The stained cells were then analysed on a
Becton Dickinson FACS Calibur Flow cytometer equipped
with a 488-nm laser. The PI red fluorescence pulse was
detected at 620 nm and the distribution of the cells in the
various cell-cycle phases was calculated by using CellFit
software.
Results
Down-regulation of endogenous Tbx3 reduces growth rate
of MECs
We applied the AS oligos designed to down-regulate Tbx3
mRNA to MECs in culture. The depletion of Tbx3 was
confirmed by qPCR analysis of cDNA derived from AS-
treated vs. untreated or S-treated cells. The reduction of Tbx3
expression in AS-treated MECs was as follows: 41±5% and
21±3% for mouse HC11 and NulliB cells, respectively
(Fig. 1a,b); 40±4% and 35±5% for rat LA7 and 106A10
cells, respectively (Fig. 1d,e); 49±5% and 52±6% for
human MCF7 and MDA435 cells, respectively (Fig. 1c,f).
Cell proliferation was estimated by determining the
number of metabolically active cells as a function of time
in culture (MTT vital stain). Treatment of HC11 cells with
the AS oligos resulted in a 38% reduction of their
monolayer growth in GM, compared with S-oligo-treated
and untreated cells (Fig. 1a). To verify that the inhibition of
monolayer growth following AS treatment was not attrib-
utable to the toxicity of AS oligos and did not reflect
activation of programmed cell death, we determined the
apoptotic rate of AS-treated HC11 cells by staining with
DAPI and directly counting apoptotic nuclei. We observed
an extremely low fraction of apoptotic nuclei (less than
0.5%), with no significant differences in the AS-treated vs.
untreated or control S-treated cells (data not shown).
Since HC11 cells harbour two mutated alleles of p53,
and since the re-introduction of WT p53 arrests their
growth (Merlo et al. 1994, 1995), we reasoned that p53
should be dispensable for Tbx3 function. To examine this,
we analysed the NulliB MEC line, derived from cultures of
MECs of p53−/− mice (Medina and Kittrell 2003). The
partial depletion of endogenous Tbx3 in NulliB cells by AS
treatment resulted in a 30±4% reduction in their monolayer
growth (Fig. 1b). These data indicated the existence of a
p53-independent Tbx3-mediated pathway of MEC growth.
We then evaluated the growth of MECs harbouring
functional WT p53, upon partial depletion of Tbx3, by
using the MCF7 human breast cancer cell line. The growth
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of these cells in the presence of AS TBX3 oligos was
reduced by 20±3% compared with S-oligo-treated and
untreated cells (Fig. 1c). Thus, relative to cells with mutated
or absent p53, AS treatment of MECs with WT p53 gave a
modest growth reduction. This may have been attributabale
to the presence of non-functional (mutated) p14ARF in
these cells (Kashuba et al. 2003), a transcriptional target of
Tbx3 (see below).
Next, we examined the growth properties of tumorigenic
MECs upon partial depletion of Tbx3 mRNA, by using the
same AS procedure as before. In this set of experiments, we
used LA7 and 106A10 rat MECs, two clones that were
derived from the Rama-25 cell line (Dulbecco et al. 1979)
and that recapitulate alveologenesis and tubulogenesis in
vitro (Zucchi et al. 1998; Dulbecco et al. 1980; Dulbecco
and Okada 1980). These cells are able to form structures
that resemble ducts (early gland development), alveoli
(lactogenic differentiation) or elongated myoepithelial cells
and have been well characterized with regard to their
proliferation, differentiation and apoptotic properties and
their distinct pattern of gene expression (Dulbecco et al.
1980; Dulbecco and Okada 1980; Zucchi et al. 1998, 1999,
2002). In these cells, Tbx3 depletion resulted in reduced cell
growth (LA7 cells: −52±6%; 106A10 cells: −64±7%;
Fig. 1d,e). Similarly, growth of NeuT-transformed HC11
cells was reduced by treatment with AS Tbx3 oligos (data
not shown). Finally, in the TBX3-expressing MDA435
mammary carcinoma cell line (with mutated p53), growth
was reduced (−42±4%) upon Tbx3 AS treatment (Fig. 1f).
Thus, the data from both tumorigenic and non-tumorigenic
MEC lines indicated that depletion of Tbx3/TBX3 led to a
reduction of cell growth in a p53-independent manner.
We subsequently carried out a cell-cycle assay on HC11
cells with depleted Tbx3 expression by means of FACS
Fig. 1 Depletion of endogenous
Tbx3 affects growth of MECs.
a–c Growth curves of murine
HC11 and NulliB MECs (a, b)
and human MCF7 MECs (c)
treated with antisense (AS) Tbx3
oligos (+AS), control sense (S)
oligos (+sense), or not treated
(N.T.). d, e Growth of LA7 and
106A10 rat MECs treated with
AS Tbx3 and control S oligos.
f Growth of MDA435 human
breast carcinoma cells treated
with AS TBX3 or control S
oligos. The p53 status of the cell
lines is indicated, if known. In
each diagram, the level of Tbx3
mRNA, determined by real-time
qPCR in treated vs. N.T. cells is
shown (insets, bottom right).
The data are reported as the
Tbx3/GAPDH ratio, the level of
Tbx3 in untreated cells being set
at 100%. g DNA cell-cycle and
forward/side scatter analysis of
control untreated (left),
AS-treated (middle) and
S-treated (right) HC11 cells at
72 h after treatment (top). The
calculated fraction of cells in
G0/G1, S and G2/M phases are
reported bottom
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analysis. DNA histograms and dot plots of the forward vs.
side-scatter of the control, AS-oligo-treated and S-oligo-
treated cells, evaluated after 72 h, are presented in Fig. 1g.
The results show that upon treatment with AS Tbx3 oligos,
the majority (90%) of the cells were in the G1 phase, with
few in the S-early phases. These data indicated the Tbx3
regulated MEC growth by controlling(directly or indirectly)
the G1/S checkpoint transition.
Differentiation and apoptosis are not affected by Tbx3
depletion
To examine the role of Tbx3 in cell differentiation, we used
the HC11 and LA7 MECs, which are able to differentiate in
vitro under specific conditions. Confluent HC11 cells start
to synthesize several milk proteins following induction with
the lactogenic hormones dexamethasone, insulin and
prolactin (DIP; Ball et al. 1988; Merlo et al. 1996). The
ability of HC11 cells to differentiate was evaluated by
detecting the expression of β-casein milk protein. First, we
determined the relative abundance of Tbx3 mRNA in
differentiating HC11 cells compared with that of unstimu-
lated cells by semi-quantative reverse transcription (RT)-
PCR. Normalized to the level of GAPDH mRNA, levels of
Tbx3 mRNA in both cells were similar (Fig. 2a). Likewise,
the human MCF10a MECs also showed no change in TBX3
expression upon confluency and DIP treatment (data not
shown). We then examined β-casein expression in HC11
cells induced to differentiate, comparing AS-oligo-treated
vs. untreated cells. No significant difference was observed
(Fig. 2b). Thus, depletion of Tbx3 mRNA in HC11 cells did
not affect either their competence to differentiate or their
response to lactogenic hormones. Next, we examined LA7
cells; these cells spontaneously undergo differentiation by
forming domes in confluent cultures, an effect that can be
enhanced by addition of DMSO, lactogenic hormones,
cAMP analogues, retinoic acid or lipids in the medium
(Dulbecco et al. 1980; Dulbecco and Okada 1980; Zucchi
et al. 2002). After reaching confluence, LA7 cells were
exposed to 2% DMSO for 48 h. No significant difference in
the number or size of domes was observed on comparing
AS-treated LA7 cells vs. untreated cells (Fig. 2c). Thus,
data from both cellular systems indicated that Tbx3
depletion did not affect significantly MEC differentiation.
Finally, we determined whether the down-regulation of
Tbx3 mRNA had any effect on the survival of MECs. We
applied conditions known to induce the apoptosis of MECs,
reminiscent of the events taking place during the post-
weaning involution of the MG (Merlo et al. 1996). We
plated HC11 cells and maintained them in the confluent
Fig. 2 Down-regulation of Tbx3 has no effect on differentiation and
apoptosis MECs. a Semi-quantitative RT-PCR analysis to detect Tbx3
mRNA in undifferentiated (lane 1) and differentiated (lane 2) HC11
cells. Amplification of β-casein mRNA is also shown to confirm
differentiation. b Western blot detection of β-casein (with anti-milk
protein antiserum) in HC11 cells, comparing AS-Tbx3-treated (left)
and untreated (right) cells. β-Actin served as loading control (N.T. not
treated). c Dome formation of LA7 cells following treatment with AS
Tbx3 oligos (left) or no treatment (right). LA7 cells were induced to
differentiate with 2% DMSO. d Right Apoptosis of HC11 cells treated
with AS Tbx3 (+AS, grey solid bars) compared with untreated cells
(open bars). Confluent cell cultures were maintained in growth
medium (GM), serum-free medium (SFM) or serum-free medium plus
epidermal growth factor (SFM+EGF). The results are expressed as the
number of apoptotic nuclei over the total number of nuclei counted, in
percent. The standard deviations of three independent experiments are
shown. Left Micrographs showing apoptotic nuclei (arrows)
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state, but deprived of serum, EGF and insulin, as described
(Merlo et al. 1996). To estimate the number of apoptotic
cells, we directly counted DAPI-stained nuclei with
morphological features of apoptosis. We observed that
AS-Tbx3-treated HC11 cells responded equally to conflu-
ence and serum/growth factor starvation, as compared with
untreated cells (Fig. 2d). Furthermore, the addition of EGF
to the starved cells restored cell survival in the presence or
absence of AS Tbx3. Therefore, Tbx3 seemed not to play an
important role in MEC apoptosis and survival.
Effect of TBX3 overexpression on MECs growth,
differentiation and apoptosis
Expression of the epitope-tagged HA-TBX3 in the HC11
MECs was achieved by introducing an expression vector
carrying the HA-TBX3 cDNA under the control of the
CMV promoter. Several clones (>30) were obtained and
analysed for the expression and nuclear localization of
HA-TBX3 by immunostaining with anti-HA antibody. Two
clones were isolated that showed HA-TBX3 expression by
Western and immunostaining analyses: clone 25 showed
HA immuoreactivity in about 60±% of the nuclei, whereas
clone 26 showed 30±5% of HA-positive nuclei (Fig. 3a,b).
No puromycin-resistent clone could be obtained that stably
expressed HA-TBX3 in all nuclei, most likely because of
the intolerance of these cells to the high expression of
TBX3. Similarly, Carlson and coauthors (2002) reported
that Tbx3 expression appeared to be toxic to C2C12
myogenic cells.
The expression of exogenous TBX3 mRNA in the
transfected clones was quantified by qPCR analysis with
primers specific to hTBX3. Clones 25 and 26 showed,
respectively, a 6-fold and 4.8-fold increase in TBX3
expression compared with endogenous hTBX3 expression
in the (human) MCF10a cells (Fig. 3a).
Clones 25 and 26 were monitored for their growth
properties in monolayers. We expected to observe a
promotion of monolayer growth in MECs expressing
exogenous TBX3. Clone 25 cells (higher HA-TBX3 expres-
sion) maintained in GM showed a 37±5% increase in their
rate of monolayer growth, whereas clone 26 cells (lower
expression) showed a 9±1% growth increase compared
with HC11 cells transfected with empty plasmid (Fig. 3c).
We examined the growth of these cells in reduced medium
conditions (1% serum, no EGF): clone 25 and 26 cells
showed, respectively, a 42±5% and a 30±4% increase in
growth rate compared with control cells (Fig. 3d).
We then tested the ability of HA-TBX3-expressing HC11
cells to differentiate following the lactogenic stimulus. We
carried out Western analysis to determine the β-casein
protein level in total extracts of clone 25 and 26 cells
treated with DIP mix. Upon induction, clone 25 and clone
26 cells were found to express β-casein to a level similar to
that of the mock cells; however, clone 25 cells showed a
slightly lower level (Fig. 3e). This reduced β-casein
expression in clone 25 cells could have simply been a
consequence of cell cloning. Nevertheless, these results
suggested that the expression of exogenous TBX3 did not
greatly affect the capacity of MECs to respond to lactogenic
hormones and initiate differentiation.
Next, we examined the apoptotic response of clone 25
and clone 26 cells to stress stimuli. We applied conditions
known to induce apoptosis in these cells (Merlo et al. 1996)
and estimated the rate of apoptosis by two independent
assays: (1) DAPI nuclear staining and the direct counting of
morphologically apoptotic nuclei and (2) flow cytometry
for Annexin V-FITC. The number of early apoptotic cells in
response to stress, as detected by flow cytometry, in clone
25 and clone 26 cells was not significantly different from
that of the parental HC11 cells (Fig. 3f, top). Similarly,
direct counting of apoptotic nuclei showed no significant
difference in the fraction of morphologically apoptotic
nuclei in clone 25 and 26 cells from that of the parental
cells (Fig. 3f, bottom), suggesting that no differences
occurred in the ability of these cells to activate their
apoptotic program in response to the withdrawal of serum/
growth factors.
TBX3-dependent regulation of ARF expression
and other members of cell-cycle regulation in MECs
In EF and other non-epithelial cells, TBX3 can repress the
expression of the cell-cycle regulatory gene ARF, resulting
in their immortalization in the presence of WT p53 (Carlson
et al. 2001; Brummelkamp et al. 2002). Both the repression
domain and the T-box (DNA-binding) domains of TBX3
are required to mediate ARF repression in EFs. Here, we
have investigated the ability TBX3 to repress transcription
of p14ARF (p19ARF in murine cells) in MECs lacking
functional p53.
Luciferase reporter assays were carried out by using a
p14ARF promoter fragment previously shown to mediate a
strong dose-dependent repression in EFs, via an element
located in the region of −19 to +54 of p14ARF (Jacobs et al.
2000; Lingbeek et al. 2002; Brummelkamp et al. 2002).
Various MEC lines were transiently co-transfected with the
ARF promoter-reporter plasmid and with 5 μg of the
HA-TBX3 expression plasmid, followed by measurement of
the relative luciferase activity in the cells. In cells lacking
WT p53, we observed a significant repression of the ARF
promoter activity by TBX3 (−77±6% and −64±5% for,
respectively, HC11 and NulliB cells; Fig. 4a). As a control,
in non-MECs, viz. COS-7 cells (harbouring inactive p53),
we observed a 50±5% inhibition of ARF promoter activity.
The tumorigenic MEC lines LA7 (unknown p53 status) and
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Fig. 3 Overexpression of HA-TBX3 promotes growth of MECs.
a Top Western blot analysis to detect HA-TBX3 fusion protein in two
clones (cl.25, cl.26) transfected with the HA-TBX3 plasmid. Expres-
sion of HA-TBX3 in transiently transfected HC11 cells and in cells
transfected with the empty vector are also shown, for comparison.
Bottom Relative abundance of exogenous HA-TBX3 mRNA compared
with endogenous TBX3 expression in the (human) MCF10a cells, as
determined by real-time qPCR. The data are represented as the ratio
TBX3/GAPDH, the expression in MCF10a cells being set to 1. In
untransfected HC11 cells, the expression of (human) TBX3 was
negligible. b Immunostaining of clone 25 (cl.25) and clone 26
(cl.26) cells compared with vector-transfected HC11 cells (bottom) to
detect HA-TBX3. Nuclei are visualized with DAPI. HA immunoreac-
tivity is localized in the nuclei. c, d Growth of HA-TBX3-expressing
clone 25 and 26 cells (cl.25, cl.26) compared with HC11 cells
transfected with vector only (HC11), in GM (c) or in reduced medium
(d). e Differentiation of clone 25 and 26 cells (cl.25, cl.26) compared
with HC11 cells transfected with vector only (HC11+vector).
Confluent cultures were incubated in DIP medium or in GM and then
analysed for β-casein expression by Western blot. β-Actin (bottom)
was used as control for sample loading. f Apoptosis of clone 25 and 26
cells (cl.25, cl.26) compared with parental HC11 cells (HC11). Top
Flow cytometry relative to clone 25 (left), clone 26 (middle) and
control HC11 cells (right), reporting propidium iodide (y axis) vs.
Annexin-V FITC (x-axis). The dots represent individual events from a
population of 10,000 events analysed. The calculated percentages of
early apoptotic cells are reported for each cell population (bottom
right). Bottom Direct counting of apoptotic nuclei in the same cell
populations as above. The results are expressed as the percentage of
apoptotic nuclei over the total number of nuclei counted. All
experiments were performed three times; the standard deviations are
shown
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MDA-435 cells (mutant p53; Docquier et al. 2005) showed
an inhibition of approximately 50% of the ARF promoter
activity by TBX3. On analysing the ARF promoter activity
in clone 25 and 26 cells expressing HA-TBX3, we observed
reduced ARF promoter transcription (−71±2% and −41±
2% in clone 25 and clone 26 cells, respectively) compared
with HC11 parental cells (Fig. 4a). The degree of ARF
promoter inhibition was correlated with the TBX3 expres-
sion level: clone 25 with higher TBX3 expression showed
stronger inhibition and vice versa. These data together
indicated that TBX3 suppressed ARF transcriptional activity
via the −19 to +54 promoter element in MECs. This
regulation took place in the absence of WT p53 and
therefore was independent of the p53 cell-cycle regulatory
pathway.
Subsequently, we investigated whether the depletion of
p19ARF mRNA could lead to the enhanced growth of
MECs. We applied an AS oligo strategy to HC11 by
designing two synthetic 21-nucleotide AS oligos specifi-
cally to target p19ARF and not p16INK4A. A 40±3%
reduction in p19ARF mRNA was observed in HC11
following AS-p19ARF-oligo treatment, in comparison with
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untreated cells, by qPCR (Fig. 4b). After 24 and 48 h of AS
treatment, HC11 cells showed, respectively, a 40±4% and a
20±2% enhancement of monolayer growth compared with
untreated cells or S-oligo-treated cells (Fig. 4b). Longer
treatment resulted in cell toxicity.
Next, we determined the rate of apoptotic death in HC11
cells upon depletion of p19ARF mRNA. p19ARF has been
shown to play a role in the balance between cell
proliferation and apoptosis during, respectively, pregnancy
and involution of the MG (Yi et al. 2004). We applied the
same conditions (as above; known to induce apoptosis) to
AS- and S-treated cells and observed a reduced induction of
apoptotic death (1.7-fold) upon depletion of p19ARF
compared with S-treated or parental cells (2.9-fold and
3.2-fold, respectively, Fig. 4b, right). These results indicated
that reduced p19ARF levels could slightly affect monolayer
cell growth independently of p53 and modified the apoptotic
response of MECs to stress stimuli.
We then determined whether altered Tbx3 expression
could affect expression of other components of cell-cycle
regulation in HC11 cells. ARF is known to associate with
Mdm2, causing its re-localization to nucleoli and prevent-
ing ubiquitination and nuclear export of p53 (Sherr 1998;
Weber et al. 1999). Active p53, in turn, promotes the
transcription of target genes, such as the CDK inhibitor
p21CIP1/WAF (Brugarolas et al. 1995), and induces growth
arrest, senescence or apoptosis. We speculated that Tbx3
might suppress transcription of p21CIP1/WAF, since Tbx2, a
T-box protein homologous to Tbx3, can repress p21CIP1/WAF
expression (Prince et al. 2004). We therefore determined the
level of endogenous expression of p19ARF, Mdm2 and
p21CIP1/WAF in HC11 cells in which endogenous Tbx3 had
been partially depleted. qPCR analysis showed a 2.2-fold
increase of p19ARF expression in HC11 treated with AS
Tbx3 oligos, compared with control cells (Fig. 4c). However,
expression of Mdm2 was not changed in the AS-Tbx3-
treated cells (Fig. 4c). Upon depletion of Tbx3, the
expression of p21CIP1/WAF in HC11 cells was elevated
two-fold, compared with control cells (Fig. 4c). Next, we
determined p19ARF, Mdm2, p21CIP1/WAF and cyclin D1
mRNA abundance in cells over-expressing HA-TBX3, by
qPCR. In clone 25 cells expressing a higher level of
HA-TBX3 (6-fold more than endogenous; Fig. 4c), we
detected a decrease (−70±3%) in the p19ARF mRNA level.
A reduced p19ARF protein level was consistently detected
in clone 25 cells by Western blot analysis (Fig. 4d).
Decreased expression of p21CIP1/WAF (−30±2%) was ob-
served in clone 25 cells (Fig. 4c), whereas no significant
changes in Mdm2 expression were detected. Finally, we
determined the expression of cyclin D1 in cells over-
expressing HA-TBX3. Cyclin D1 is one of the main
regulators of the G1/S-phase transition (Resnitzky and Reed
1995) and is over-expressed in a high fraction of breast
tumor cell lines and primary tumors (Weinstat-Saslow et al.
1995). We observed a three-fold increased level of cyclin
D1 mRNA in clone 25 cells compared with that of parental
cells, consistent with reported data on the repression of
cyclin D1 by p19ARF utilizing both the p53-dependent and
-independent pathways (D’Amico et al. 2004). Similar
results were obtained with clone 26 with less drastic changes
(data not shown). Taken together, these data indicated that
TBX3 could regulate p19ARF, p21CIP1/WAF and cyclin D1
expression in MECs lacking functional WT p53, irrespective
of the Mdm2-p53-dependent pathway.
Finally, we examined the expression of Tbx3 and
p19ARF within the context of a tissue subjected to
physiological stimuli. We extracted RNA from MGs at
various postnatal stages, including virgin (10 weeks), mid-
pregnancy (10 days), late pregnancy (15 days), lactation
(2–4 days) and involution (2 days) stages. We then
compared the relative abundance of Tbx3 and p19ARF
mRNA by qPCR. The Tbx3 mRNA level was slightly
higher in virgin MGs but then declined during pregnancy
and remained nearly unchanged in all subsequent steps
RFig. 4 TBX3 negatively regulates the ARF promoter, irrespective of
p53 and Mdm2. a Left Repression of the (−19/+54) ARF promoter by
TBX3 (5) in MEC lines and COS-7 cells by luciferase-reporter assay
(black bars). The basal promoter activity (transfection with empty
vector) is set at 100% in each case (0). Right Level of the (−19/+54)
p14ARF promoter activity in clone 25 and 26 cells (light grey bars).
Experiments were performed at least three times; the standard
deviations are indicated. b Left Growth curves of HC11 treated with
AS p19ARF (+ASp19) and control S oligos (+sense p19) compared
with that of parental HC11 (N.T.). The level of p19ARF mRNA
determined by real-time qPCR in treated vs. N.T. cells is shown in the
insets (bottom right). The data are reported as the p19ARF/GAPDH
ratio, the level of p19ARF in untreated cells being set at 100%. Right
Apoptosis assay of HC11 cells treated with AS p19ARF (+AS)
compared with cells treated with S oligos (+S) and with parental
HC11 cells. The experimental conditions were the same as in Fig. 1k.
Fold change is shown, compared between the effect on apoptotic rate
in SFM and GM. The standard deviations between independent
experiments are shown. c Endogenous levels of Tbx3, p19ARF,
Mdm2, p21CIP1/WAF and cyclin D1 mRNAs determined by real-time
qPCR in HC11 cells treated with AS Tbx3 and in clone 25 cells
expressing exogenous HA-TBX3. Values were normalized to GAPDH
mRNA. The level of mRNAs in parental HC11 cells was set at 1
(horizontal dashed line). For quantification of TBX3 expression in
clone 25 cells, the endogenous level of TBX3 in human MCF10a cells
served as a control and was set at 1. The standard deviations between
independent experiments are shown. d Western blot detection of
p19ARF in clone 25 (cl.25) cells (middle lane), in HC11 transiently
transfected with HA-TBX3 (right lane) and in HC11 cells transfected
with empty expression vector (left lane). The β-actin level served as a
loading control. e In vivo expression of Tbx3 and p19ARF during
postnatal maturation of the mammary gland. Gland nos. 4–5 from WT
adult females, at the indicated stages (mid. middle, pregn. pregnancy,
lactat. lactation, involut. involution) were dissected, pooled, extracted
for RNA and analysed by real-time qPCR (see Materials and
methods). The relative abundance of Tbx3 and p19ARF, normalized
to GAPDH mRNA, is shown. A calibration sample was used (a mixed
pool of cDNAs from all stages); the mRNA abundance was set at 1
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(Fig. 4e). The p19ARF mRNA level was nearly undetect-
able in virgin glands, increased at mid-pregnancy and
declined at late pregnancy. During lactation (2–4 days) and
involution (2 days), an increase was observed in the relative
p19ARF mRNA level (Fig. 4e). These data indicated that
Tbx3 expression in normal MGs remained unchanged
during its maturation stages and was sufficient to provide
the MECs with the growth properties characteristic of that
stage. Hence, Tbx3 expression is unlikely to be hormonally
controlled, whereas p19ARF expression is known to
respond to hormonal changes during pregnancy, as is
consistent with our results.
Discussion
Haploinsufficiency of the TBX3 gene product is the
recognized cause of UMS. The breast defects in UMS
patients vary from mild hypoplasia to the absence of the
areola and the inability to lactate (Bamshad et al. 1997,
1999; Meneghini et al. 2006). In mice with homozygous
inactivation of Tbx3, the MGs fail to develop altogether,
whereas mild defects in MG development are observed in
heterozygous adult females (Davenport et al. 2003; Jerome-
Majewska et al. 2005). Since TBX3 is expressed in the
MECs of the ductal and lobule-alveolar system (Davenport
et al. 2003; Chapman et al. 1996), a cell-autonomous role of
this transcription factor in regulating the growth of MECs
seems obvious, although a direct demonstration is lacking.
Here, we have addressed the cellular functions of TBX3 by
using several MEC lines in vitro. We show that TBX3
inhibits the transcription of ARF and promotes cell growth
independently of the p53 pathway of cell-cycle regulation.
These observations suggest that the Tbx3 expression level is
critical for confering growth ability on MECs. Since the
cellular targets of TBX3 mutations in vivo are the limb buds
and the apocrine glands, and in particular the MG, we
considered it rational to establish Tbx3 function in MECs.
By altering Tbx3 expression, we show for the first time an
involvement of Tbx3 in the regulation of MEC growth.
MECs appear to use a pathway distinct from that known
in EFs or other non-epithelial cells (Carlson et al. 2001;
Brummelkamp et al. 2002; Lingbeek et al. 2002), as TBX3
controls the growth rate independently of p53. To establish
this, we have used MEC lines that harbour WT (MCF7) or
mutated p53 (HC11, MDA435) or that are devoid of p53
(NulliB). All these cell lines are sensitive to the AS-
mediated down-regulation of Tbx3 expression. Similarly,
the growth of osteoblasts and bladder cells with mutated
p53 is inhibited upon depletion of Tbx3 (Govoni et al.
2006; Ito et al. 2005). To reinforce the point that TBX3 acts
in a p53-independent way, the absence of p53 cannot rescue
the mild MG phenotype observed in Tbx3+/− mice
(Jerome-Majewska et al. 2005). As we have excluded
p53, Tbx3-mediated MECs growth is likely to entail the
repression or activation of other growth regulatory proteins.
We have examined the expression of the cell-cycle negative
regulator p19ARF. This gene is regulated by Tbx2 and
Tbx3 in non-epithelial cells, acts upstream of p53 and can
lead to cell immortalization when abnormally expressed
(Carlson et al. 2001; Brummelkamp et al. 2002; Lingbeek
et al. 2002; Carnero et al. 2000). Here, we show that Tbx3
represses ARF transcription in MECs via the (−19/+54)
promoter element; the data have been confirmed by the up-
regulation of endogenous p19ARF mRNA in cells with a
reduced level of Tbx3 mRNA. Consistent with the finding
that p19ARF represses the expression of cyclin D1
(D’Amico et al. 2004), we have detected increased cyclin
D1 expression in HC11 cells over-expressing TBX3.
Finally, we have demonstrated that the depletion of
endogenous p19ARF in MECs results in a slight promotion
of cell growth. Moreover, in MCF7 cells, which contain
WT p53 but mutated p14ARF (Kashuba et al. 2003), the
depletion of endogenous TBX3 results in a modest
inhibition of growth compared with that of other MECs.
Collectively, these results indicate that Tbx3 utilizes a
p19ARF-dependent p53-independent pathway to control
MEC growth.
ARF is commonly accepted to induce p53-dependent
growth arrest by sequestering the p53 antagonist Mdm2
protein in the nucleolus (Sherr 1998; Weber et al. 1999). In
EFs with WT p53, the down-regulation of ARF leads to an
extended lifespan and cell immortalization (Carnero et al.
2000). On the contrary, our data on MECs indicate that WT
p53 is not required for Tbx3-ARF-mediated growth
regulation. Alternatively, p53-independent ARF functions
have been recognized: the reintroduction of p19ARF in EFs
lacking p53, Mdm2 and p19ARF arrests their proliferation
(Weber et al. 2000). Several other mechanisms and targets
have also been proposed (Datta et al. 2002; Normand et al.
2005; Sugimoto et al. 2003; Yarbrough et al. 2002)
highlighting the complexity of p19ARF functions and
suggesting the existence of distinct cell-type-specific path-
ways. By using appropriate cell models, such as MECs as
opposed to EFs, some hypotheses regarding cell-cycle
regulation may therefore need to be re-assesses.
We have evaluated the expression of Mdm2 and
p21CIP1/WAF; two cell-cycle control proteins that utilize both
p53-dependent and -independent pathways. ARF is thought
to neutralize the activity of Mdm2, an oncoprotein involved
in a negative feedback loop with p53 (Momand and Zambetti
1997). Mdm2 has also been shown to be an effector of
p19ARF in the absence of WT p53 (Steinman et al. 2004).
We have found no significant change in Mdm2 expression
upon alteration of Tbx3 expression, thus excluding its
Tbx3-dependency and indicating an Mdm2-independent
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ARF function (Korgaonkar et al. 2002). p21CIP1/WAF is a
cyclin-CDK inhibitor that mediates p53-dependent growth
arrest and that has been implicated in cellular senescence
(Brown et al. 1997; Gartel and Tyner 2002). p21CIP1/WAF
can also be activated by p53-independent stimuli leading to
growth arrest, apoptosis or cell differentiation (Wang et al.
1999). We have observed changes in p21CIP1/WAF levels
following altered Tbx3 expression, consistent with an
inhibitory function of Tbx3 on p21CIP1/WAF and with the
increase of the growth rate of these cells. Interestingly, in
melanoma cells, p21CIP1/WAF is repressed by Tbx2, a gene
highly homologous to Tbx3 (Prince et al. 2004). Further
analyses are needed to clarify whether the Tbx3-mediated
regulation of p21CIP1/WAF in MECs is direct and to identify
additional Tbx3 downstream targets.
We have examined the effect of Tbx3 over-expression or
depletion on cell differentiation and apoptosis. HC11 and
LA7 cells have provided us with two independent models
of in vitro differentiation (Merlo et al. 1995; Zucchi et al.
1998), although alterations in Tbx3 levels do not result in
significant changes. We have also applied conditions
known to induce apoptosis in HC11 cells, reminiscent of
the events that take place during post-weaning involution of
the MG (Merlo et al. 1996). Alterations of the Tbx3 mRNA
level have no significant effect on the ability of HC11 cells
to activate their apoptotic program. The same results have
been obtained with other MEC lines (N. Platonova,
unpublished data). Finally, the endogenous expression of
Tbx3 in differentiating HC11 cells and in murine MGs
during various physiological phases (virgin, pregnancy,
lactation and involution) does not change. Thus, the only
function of TBX3/Tbx3 in MECs appears to be the control
of growth properties.
During MG development, the first phase of epithelial
cell proliferation is hormone-independent and generates the
primitive ductal tree, the alveolar structure and the end
buds. A second and a third phase occur, respectively, at
puberty and during pregnancy and are hormone-dependent.
The role of Tbx3, p19ARF and p21CIP1/WAF1 in the
expansion of the MEC population and in their differentia-
tion and apoptosis in vivo is far from being understood. In
p19ARF−/− mice, MGs grow and differentiate normally,
with no obvious defects (Jerome-Majewska et al. 2005; Yi
et al. 2004). However, in the absence of p19ARF, a larger
number of MECs are in S-phase during pregnancy, whereas
MECs from ARF−/− MGs readily give rise to immortalized
clones in vitro, as do the p53−/− MECs (Yi et al. 2004;
Jerry et al. 1998). Thus, p19ARF negatively contributes to
the maintenance of a normal proliferation rate. On the
contrary, p19ARF expression is low or undetectable in
quiescent MECs, increases during mid-pregnant prolifera-
tion and is stimulated by hormone treatment (Sherr 1998;
Yi et al. 2004). Therefore, the possible cell-cycle inhibitory
function of p19ARF during pregnancy-dependent MEC
proliferation is not consistent with its expression profile.
The proliferation of MECs within the MG tissues is likely
to entail higher-order regulation that depends upon tissue
interactions and hormonal stimulation.
The up-regulation of p19ARF during pregnancy might
reflect expression in non-epithelial cells (i.e. stromal
cells). Indeed, Tbx2 is mainly expressed in the stromal
compartment of the MG (Chapman et al. 1996) and Tbx2
can repress ARF transcription in vitro (Paxton et al. 2002;
Jacobs et al. 2000). Coincidently with the rise in p19ARF
expression, Tbx2 is down-regulated at mid-pregnancy
(N. Platonova, unpublished data), further supporting the
possibility that transcription regulation of ARF involves
similar, but not identical, molecules in different cell
types.
A more evident function of p19ARF in the adult MG is
related to the activation of apoptosis during the post-
weaning involution phase. In ARF−/− adult females, a
reduced number of MECs undergoes apoptosis (Yi et al.
2004) and p19ARF expression is elevated during late
involution, as compared with resting glands (Yi et al.
2004). This phenotype is shared with p53−/− mice, which
also show delayed MG involution (Jerry et al. 1998). Tbx3
is unlikely to play a role in this process, as we have seen no
significant changes in Tbx3 expression in normal MGs
during involution and no changes in the apoptotic response
of MECs to stress conditions when Tbx3 expression is
altered.
The partial down-regulation of Tbx3 mRNA results in
reduced MECs growth. Several human disorders linked to
T-box gene mutations reveal a mechanism of haploinsuffi-
ciency (Packham and Brook 2003). Such is the case for
TBX5 in Holt-Horam syndrome (OMIM 142900; Basson et
al. 1997; Li et al. 1997) and for TBX1 in the DiGeorge-
related syndromes (OMIM 188400, 192430, 217095;
Jerome and Papaioannou 2001; Lindsay et al. 2001;
Merscher et al. 2001). In X-linked cleft palate/ankyloglos-
sia (OMIM 303400), a fraction of women with mutated
TBX22 exhibit the phenotype, suggesting haploinsuffi-
ciency with low penetrance (Braybrook et al. 2001;
Marcano et al. 2004). The underlying notion is that the
cellular level of the T-box gene products must be finely
regulated to ensure proper cell growth, morphogenesis and
differentiation.
Haploinsufficiency has been thought to be a feature of
human pathologies, since mice heterozygous for the
inactivation of Tbx1, Tbx3 and Tbx4 exhibit minimal or
no evident defects (Jerome and Papaioannou 2001; Lindsay
et al. 2001; Merscher et al. 2001; Davenport et al. 2003;
Naiche and Papaioannou 2003). However, Tbx5del/+ mice
show all the phenotypes of Holt-Horam patients (Bruneau et
al. 2001; Moskowitz et al. 2004), and the MGs of Tbx3+/−
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adult mice develop normally but show reduced ductal
branching (Jerome-Majewska et al. 2005). This indicates
that half of the normal dose of Tbx3 is not sufficient to
complete postnatal morphogenesis of the gland epithelium.
In these mice, however, the effect of Tbx3 hemizygosity on
pregnancy, lactation and involution and on the expression
of p19ARF have not been examined and could be highly
informative.
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